Many academic and private-sector RNAi researchers believe that HIV is one of the most promising targets for RNAi-based therapeutic intervention. One of these is Irvin Chen, director of the UCLA AIDS Institute, who has recently begun testing a stem cell-based RNAi treatment in monkeys, and presented in vitro data at the first meeting of the Oligonucleotide Therapeutics Society last week in New York City.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.